Wyeth sues J&J over stent drug
Wyeth sues Johnson & Johnson in Delaware federal court Oct. 26, seeking to break agreement to supply J&J's Cordis unit with Rapamune (sirolimus), the immunosuppressant used on the Cypher drug-eluting stent. Suit alleges material breach of contract and seeks damages, charging Cordis with failing to make "commercially reasonable" efforts to develop CCI 779, a sirolimus analog, as required under their agreement...
You may also be interested in...
Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.